Alvotech business relationships
Companies named in Alvotech’s 20-F filed 2026-03-31, and public companies whose annual reports name Alvotech. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Alvotech’s annual report 7
“On 29 January 2026, the Group announced that it had entered into a settlement and licensing agreement with Regeneron and Bayer regarding AVT06, its proposed biosimilar to Eylea (aflibercept), which is approved for marketing in the European Economic Area, United Kingdom and Japan.” SEC filing
“In December 2025, Alvotech and Teva reached a settlement and license agreement with Regeneron Pharmaceuticals Inc. concerning the launch of AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept) in the United States.” SEC filing
“In Japan, in October 2025, Regeneron and Bayer brought a petition for provisional disposition against Alvotech's commercial partner Fuji Pharma based on Japanese patent no.” SEC filing
“In Japan, in October 2025, Regeneron and Bayer brought a petition for provisional disposition against Alvotech's commercial partner Fuji Pharma based on Japanese patent no.” SEC filing
“Settlement and License Agreement between Alvotech hf. and AbbVie, dated March 8, 2022” SEC filing
“While our legal proceedings adverse to AbbVie related to our biosimilar adalimumab product, AVT02, have been settled or otherwise resolved in the United States, the Netherlands, and Japan, and before the European Patent Office, proceedings between our Canadian partner JAMP and AbbVie are pending in...” SEC filing
“In 2023, we announced an agreement with Kashiv Biosciences LLC ("Kashiv") to in-license AVT23.” SEC filing
Companies whose annual reports name Alvotech 3
“On December 19, 2025, Alvotech and Teva announced that they have reached a settlement and license agreement with Regeneron Pharmaceuticals Inc., concerning the launch of Alvotech's proposed biosimilar to Eylea” SEC filing
“...sed biosimilar to Prolia ® (denosumab) and to Xgeva ® (denosumab) were submitted for regulatory review in the U.S. Our proposed biosimilars to Simponi ® , Simponi Aria ® (golimumab), and Eylea ® (aflibercept), which are in collaboration with Alvotech, were submitted for regulatory review in the U.S.” SEC filing
“primarily through development and commercialization partnerships, , such as our 2024 partnership with Alvotech for the commercialization of a biosimilar candidate to Prolia® and Xgeva® (denosumab) in the United States and Europe, and our 2025 partnership with Shanghai Henlius Biotech, Inc. for the c...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.